Mobile site search icon.
Mobile navigation icon.

TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.

TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.

STAY UP TO DATE

Sign up to get news about TAKHZYRO as it becomes available, as well as information about hereditary angioedema (HAE).

All fields are required unless otherwise noted.

Specialty

Your privacy is important to us. For more information, please refer to our Privacy Notice. To manage your communication preferences visit our preference center.

By providing your information you certify that you are a healthcare provider.